Protagonist Therapeutics, Inc. (PTGX)
USD 44.78
(-2.98%)
USD 44.78
(-2.98%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -70.23 Million | -108.13 Million | -107.86 Million | -72.48 Million | -41.52 Million | -49.94 Million |
| Net Income | -78.95 Million | -127.39 Million | -125.55 Million | -66.15 Million | -77.18 Million | -38.92 Million |
| Depreciation & Amortization | 3.31 Million | 3.36 Million | 2.77 Million | 2.56 Million | 2.49 Million | 527 Thousand |
| Deferred income taxes | 2.86 Million | - | - | 1.43 Million | -775 Thousand | -658 Thousand |
| Stock-based compensation | 29.29 Million | 24.2 Million | 16.39 Million | 7.89 Million | 8.35 Million | 6.91 Million |
| Change in working capital | -19.51 Million | -7.76 Million | -3.31 Million | -19.01 Million | 26.14 Million | -18.01 Million |
| Other non-cash items | -7.24 Million | -549 Thousand | 1.83 Million | 781 Thousand | -557 Thousand | 206 Thousand |
| Investing Cash Flow | -39.25 Million | 91.46 Million | -15.86 Million | -90.96 Million | -53.71 Million | 2.21 Million |
| Investments in PPE | -609 Thousand | -795 Thousand | -1.1 Million | -471 Thousand | -967 Thousand | -486 Thousand |
| Acquisitions | 38.64 Million | -91.46 Million | 14.75 Million | 90.49 Million | 52.74 Million | - |
| Investment purchases | -191.04 Million | -214.87 Million | -286.58 Million | -280.02 Million | -166.93 Million | -71.06 Million |
| Sales/Maturities of investments | 152.39 Million | 307.13 Million | 271.83 Million | 189.53 Million | 114.19 Million | 73.75 Million |
| Other Investing Activities | -38.64 Million | 91.46 Million | -14.75 Million | -90.49 Million | -52.74 Million | 2.69 Million |
| Financing Cash Flow | 170.47 Million | 18.83 Million | 129.92 Million | 247.62 Million | 46.03 Million | 24.11 Million |
| Debt repayment | - | - | - | -10.52 Million | -9.76 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -769 Thousand | -188 Thousand | -189 Thousand | - | - | - |
| Common Stock Issuance | 171.24 Million | 19.02 Million | 130.11 Million | 255.36 Million | 34.49 Million | 23.18 Million |
| Other Financing Activities | 171.24 Million | 19.02 Million | 130.11 Million | 2.78 Million | 21.3 Million | 934 Thousand |
| Accounts receivables | -9.99 Million | 4.24 Million | -915 Thousand | 3.33 Million | -757 Thousand | -2.77 Million |
| Accounts payables | -2.86 Million | 2.04 Million | -1.39 Million | 309 Thousand | -3 Million | 4.43 Million |
| Inventory | -9.52 Million | -4.24 Million | 915 Thousand | -3.33 Million | 757 Thousand | 3.85 Million |
| Other working capital | 2.86 Million | -9.81 Million | -1.92 Million | -19.32 Million | 29.14 Million | -23.52 Million |
| Cash at beginning of period | 125.96 Million | 123.89 Million | 117.81 Million | 33.46 Million | 82.69 Million | 106.48 Million |
| Cash at end of period | 186.95 Million | 125.96 Million | 123.89 Million | 117.81 Million | 33.46 Million | 82.69 Million |
| Capital Expenditure | -609 Thousand | -795 Thousand | -1.1 Million | -471 Thousand | -967 Thousand | -486 Thousand |
| Effect of forex changes on cash | - | -90 Thousand | -126 Thousand | 175 Thousand | -26 Thousand | -177 Thousand |
| Net cash flow / Change in cash | 60.98 Million | 2.07 Million | 6.07 Million | 84.35 Million | -49.22 Million | -23.79 Million |
| Free Cash Flow | -70.84 Million | -108.93 Million | -108.96 Million | -72.95 Million | -42.49 Million | -50.43 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -30.61 Million | 207.34 Million | 27.33 Million | -78.95 Million | -34.1 Million | -38.46 Million |
| Depreciation & Amortization | 892 Thousand | 820 Thousand | 832 Thousand | 3.31 Million | 827 Thousand | 821 Thousand |
| Deferred income taxes | - | - | 6.8 Million | 2.86 Million | -6.8 Million | - |
| Stock-based compensation | 8.94 Million | 9.35 Million | 6.6 Million | 29.29 Million | 6.76 Million | 8.34 Million |
| Change in working capital | 291.06 Million | -243.32 Million | -16.46 Million | -19.51 Million | 908 Thousand | 4.01 Million |
| Other non-cash items | -290.73 Million | 296.59 Million | -1.34 Million | -7.24 Million | 5.79 Million | -960 Thousand |
| Investing Cash Flow | -88.11 Million | 6.07 Million | -61.28 Million | -39.25 Million | -13.55 Million | 25.76 Million |
| Investments in PPE | -28 Thousand | -242 Thousand | -19 Thousand | -609 Thousand | -404 Thousand | -176 Thousand |
| Acquisitions | - | - | 61.26 Million | 38.64 Million | 13.15 Million | -25.93 Million |
| Investment purchases | -174.95 Million | -65.67 Million | -97.96 Million | -191.04 Million | -58.95 Million | -6.06 Million |
| Sales/Maturities of investments | 86.86 Million | 71.98 Million | 36.7 Million | 152.39 Million | 45.8 Million | 32 Million |
| Other Investing Activities | -88.09 Million | 6.31 Million | -61.26 Million | -38.64 Million | -13.15 Million | 25.93 Million |
| Financing Cash Flow | 2.57 Million | 7.19 Million | 527 Thousand | 170.47 Million | 35.31 Million | 108.17 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -600 Thousand | 769 Thousand | -769 Thousand | - | -669 Thousand |
| Common Stock Issuance | 2.57 Million | 7.79 Million | 527 Thousand | 171.24 Million | 35.31 Million | 108.84 Million |
| Other Financing Activities | 2.57 Million | -600 Thousand | 527 Thousand | 171.24 Million | 35.31 Million | 108.84 Million |
| Accounts receivables | 300 Million | -290.04 Million | -10 Million | -9.99 Million | 39 Thousand | 12 Thousand |
| Accounts payables | -201 Thousand | 2.82 Million | -597 Thousand | -2.86 Million | -3.2 Million | 552 Thousand |
| Inventory | - | - | 10 Million | -9.52 Million | - | -12 Thousand |
| Other working capital | -8.73 Million | 43.89 Million | -15.86 Million | 2.86 Million | 4.07 Million | 3.46 Million |
| Cash at beginning of period | 172.56 Million | 186.72 Million | 230.75 Million | 125.96 Million | 235.6 Million | 127.91 Million |
| Cash at end of period | 355.64 Million | 172.56 Million | 186.95 Million | 186.95 Million | 230.75 Million | 235.6 Million |
| Capital Expenditure | -28 Thousand | -242 Thousand | -19 Thousand | -609 Thousand | -404 Thousand | -176 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 183.07 Million | -14.15 Million | -43.8 Million | 60.98 Million | -4.85 Million | 107.69 Million |
| Free Cash Flow | 268.59 Million | -27.67 Million | 16.94 Million | -70.84 Million | -27.01 Million | -26.41 Million |
IPB
2337
SJM
3913
STX
0VBE